J.P. Morgan Remains Bullish on IDEAYA Biosciences (IDYA)

Group 1 - IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is recognized as a promising biotech stock with high potential, receiving a Buy rating from J.P. Morgan analyst Anupam Rama with a price target of $74 [1] - The bullish rating is supported by anticipated updates on the company's lead asset, darovasertib, which is expected to create significant value [2] - UBS analyst David Dai also reiterated a Buy rating for IDEAYA Biosciences with a price target of $50, highlighting the company's focus on oncology precision medicine and targeted therapeutics [3] Group 2 - IDEAYA's product candidate, IDE196, is a protein kinase C inhibitor targeting genetically defined cancers associated with GNAQ or GNA11 gene mutations [3]